BRPI0516995A - composto que tem a estrutura - Google Patents
composto que tem a estruturaInfo
- Publication number
- BRPI0516995A BRPI0516995A BRPI0516995-0A BRPI0516995A BRPI0516995A BR PI0516995 A BRPI0516995 A BR PI0516995A BR PI0516995 A BRPI0516995 A BR PI0516995A BR PI0516995 A BRPI0516995 A BR PI0516995A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- patient
- vascular permeability
- inhibiting
- carbon atoms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000008728 vascular permeability Effects 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTO QUE TEM A ESTRUTURA: CAMPOSIçãO FARMACêUTICA QUE COMPREENDE O DITO COMPOSTO; COMPOSIçãO FARMACêUTICA QUE COMPREENDE UMA QUANTIDADE INIBIDORA DA PERMEABILIDADE VASCULAR DO DITO COMPOSTO; USO DO DITO COMPOSTO; MéTODO PARA PROPORCIONAR NEUROPROTEçAO EM UM PACIENTE; MéTODO PARA INIBIR DEFICITS NEUROLóGICOS EM UM PACIENTE; MéTODO PARA REDUZIR VOLUMES DE INFARTOS EM UM PACIENTE; E MéTODO PARA INIBIR A PERMEABILIDADE VASCULAR PóS-ISQUêMICA DE VASOS SANGUìNEOS CEREBRAIS EM UM PACIENTE Esta invenção refere-se a compostos da fórmula: onde: R é metila ou etila; R' e R" são independentemente alquila com 1 a 3 átomos de carbono, ou R' e R", em conjunto com o nitrogênio ao qual eles estão anexados, podem formar um anel saturado de 5 ou 6 membros, que pode conter opcionalmente um heteroátomo adicional selecionado entre NR "', O ou S(O)~ n~; n é 0-2; e R"' é hidrogênio ou alquila com 1 a 3 átomos de carbono; e seus sais farmaceuticamente aceitáveis, e seu uso para inibir a permeabilidade vascular causada por doença, lesão ou outro traumatismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62128004P | 2004-10-22 | 2004-10-22 | |
| PCT/US2005/037839 WO2006047262A1 (en) | 2004-10-22 | 2005-10-21 | 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516995A true BRPI0516995A (pt) | 2008-09-30 |
Family
ID=35784691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516995-0A BRPI0516995A (pt) | 2004-10-22 | 2005-10-21 | composto que tem a estrutura |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20060116375A1 (pt) |
| EP (1) | EP1802581B1 (pt) |
| JP (1) | JP2008517924A (pt) |
| KR (1) | KR20070085413A (pt) |
| CN (1) | CN101044117A (pt) |
| AT (1) | ATE391122T1 (pt) |
| AU (1) | AU2005299822A1 (pt) |
| BR (1) | BRPI0516995A (pt) |
| CA (1) | CA2581807A1 (pt) |
| CR (1) | CR9072A (pt) |
| DE (1) | DE602005005843T2 (pt) |
| DK (1) | DK1802581T3 (pt) |
| EC (1) | ECSP077385A (pt) |
| ES (1) | ES2303287T3 (pt) |
| HK (1) | HK1104555A1 (pt) |
| IL (1) | IL182547A0 (pt) |
| MX (1) | MX2007004833A (pt) |
| NO (1) | NO20071708L (pt) |
| PL (1) | PL1802581T3 (pt) |
| PT (1) | PT1802581E (pt) |
| RU (1) | RU2007111704A (pt) |
| SI (1) | SI1802581T1 (pt) |
| WO (1) | WO2006047262A1 (pt) |
| ZA (1) | ZA200703275B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| CN102952037A (zh) * | 2012-11-18 | 2013-03-06 | 大连九信生物化工科技有限公司 | 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法 |
| WO2014086284A1 (zh) * | 2012-12-04 | 2014-06-12 | 上海医药集团股份有限公司 | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 |
| CN114436851B (zh) * | 2022-01-17 | 2023-08-22 | 常州大学 | 一种n,n-二甲基苄胺及其衍生物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20040229880A1 (en) * | 2003-02-21 | 2004-11-18 | Wyeth | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
-
2005
- 2005-10-21 EP EP05820982A patent/EP1802581B1/en not_active Not-in-force
- 2005-10-21 DK DK05820982T patent/DK1802581T3/da active
- 2005-10-21 AT AT05820982T patent/ATE391122T1/de not_active IP Right Cessation
- 2005-10-21 ES ES05820982T patent/ES2303287T3/es active Active
- 2005-10-21 RU RU2007111704/04A patent/RU2007111704A/ru not_active Application Discontinuation
- 2005-10-21 AU AU2005299822A patent/AU2005299822A1/en not_active Abandoned
- 2005-10-21 BR BRPI0516995-0A patent/BRPI0516995A/pt not_active IP Right Cessation
- 2005-10-21 CA CA002581807A patent/CA2581807A1/en not_active Abandoned
- 2005-10-21 WO PCT/US2005/037839 patent/WO2006047262A1/en active Application Filing
- 2005-10-21 CN CNA2005800360383A patent/CN101044117A/zh active Pending
- 2005-10-21 PL PL05820982T patent/PL1802581T3/pl unknown
- 2005-10-21 KR KR1020077011472A patent/KR20070085413A/ko not_active Application Discontinuation
- 2005-10-21 JP JP2007538054A patent/JP2008517924A/ja not_active Withdrawn
- 2005-10-21 SI SI200530255T patent/SI1802581T1/sl unknown
- 2005-10-21 DE DE602005005843T patent/DE602005005843T2/de active Active
- 2005-10-21 MX MX2007004833A patent/MX2007004833A/es active IP Right Grant
- 2005-10-21 PT PT05820982T patent/PT1802581E/pt unknown
- 2005-10-21 US US11/255,556 patent/US20060116375A1/en not_active Abandoned
-
2007
- 2007-03-30 NO NO20071708A patent/NO20071708L/no not_active Application Discontinuation
- 2007-04-11 EC EC2007007385A patent/ECSP077385A/es unknown
- 2007-04-12 IL IL182547A patent/IL182547A0/en unknown
- 2007-04-20 ZA ZA200703275A patent/ZA200703275B/xx unknown
- 2007-04-20 CR CR9072A patent/CR9072A/es not_active Application Discontinuation
- 2007-11-27 HK HK07112929A patent/HK1104555A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL1802581T3 (pl) | 2008-09-30 |
| SI1802581T1 (sl) | 2008-08-31 |
| EP1802581A1 (en) | 2007-07-04 |
| DK1802581T3 (da) | 2008-06-30 |
| PT1802581E (pt) | 2008-06-03 |
| ECSP077385A (es) | 2007-05-30 |
| CN101044117A (zh) | 2007-09-26 |
| CR9072A (es) | 2007-09-07 |
| US20060116375A1 (en) | 2006-06-01 |
| KR20070085413A (ko) | 2007-08-27 |
| JP2008517924A (ja) | 2008-05-29 |
| ATE391122T1 (de) | 2008-04-15 |
| EP1802581B1 (en) | 2008-04-02 |
| MX2007004833A (es) | 2007-05-16 |
| AU2005299822A1 (en) | 2006-05-04 |
| IL182547A0 (en) | 2007-09-20 |
| DE602005005843D1 (de) | 2008-05-15 |
| HK1104555A1 (en) | 2008-01-18 |
| NO20071708L (no) | 2007-07-13 |
| WO2006047262A1 (en) | 2006-05-04 |
| CA2581807A1 (en) | 2006-05-04 |
| ES2303287T3 (es) | 2008-08-01 |
| DE602005005843T2 (de) | 2009-05-14 |
| ZA200703275B (en) | 2008-08-27 |
| RU2007111704A (ru) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0407810A (pt) | composto, composição farmacêutica, ativador da glicocinase, e, medicamento | |
| BRPI0718247A2 (pt) | Compostos 3-isobutil-9,10-dimetóxi-1,3,4,6,7,11b-hexaidro-2h-pirid o[2,1-a]isoquinolin-2-ol substituídos e métodos relacionados aos mesmos | |
| BRPI0409117A (pt) | compostos n-heterocìclios condensados e seu uso como antagonistas do receptor de crf | |
| DK1326613T4 (da) | Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering | |
| BRPI0821115A8 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
| WO2006136837A3 (en) | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | |
| BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
| BRPI0516995A (pt) | composto que tem a estrutura | |
| BRPI0607701A2 (pt) | composto ou um sal, éster, solvato, estereoisÈmero, tautÈmero ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade antibacterialmente eficaz de um composto junto com um veìculo farmaceuticamente aceitável, e, método de preparação de um composto | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| BRPI0517100A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência | |
| BRPI0413013A (pt) | composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| RU2011139157A (ru) | Производное трициклического пиразолопиримидина | |
| BR9909086A (pt) | Derivados de piperidinila e n-amidinopiperidinila | |
| Furuhata et al. | Histamine-releasing properties of T-3762, a novel fluoroquinolone antimicrobial agent in intravenous use. I. Effects of doses and infusion rate on blood pressure, heart rate and plasma histamine concentration | |
| BR0012093A (pt) | Composto tricìclico tendo união espiro | |
| AR070949A1 (es) | Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso | |
| BR0209332A (pt) | Derivados de ftalazina com atividade inibidora da angiogênese | |
| EA200600022A1 (ru) | Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций | |
| CN105985354B (zh) | 嘧啶衍生物、细胞毒性剂、药物组合物及其应用 | |
| NO20021337D0 (no) | 4-benzylaminoquinolinkonjugater med gallesyre og deres heteroanaloger, fremgangsmåte for deres fremstilling, legemidlersom inneholder disse forbindelser og deres anvendelse | |
| EA201000832A1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции | |
| BRPI0415546A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |